Рак молочной железы

Study challenges treatment approach for rare triple-negative breast cancer

Study challenges treatment approach for rare triple-negative breast cancer FemTech World

Breast cancer study uncovers potential new Achilles’ heel for cancer cells

Breast cancer study uncovers potential new Achilles’ heel for cancer cells The Institute of Cancer Research

Как агрессивный рак груди проникает в мозг: исследование

Как агрессивный рак груди проникает в мозг: исследование Наука Mail

Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum

Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum Nature

Breast cancer can behave differently in older women. This physician is making more tailored treatments a reality

Breast cancer can behave differently in older women. This physician is making more tailored treatments a reality STAT

Six ways U of A researchers are leading the way to better breast cancer treatment

Six ways U of A researchers are leading the way to better breast cancer treatment University of Alberta

В Восточном Казахстане рак молочной железы на I стадии регистрируют у 58% женщин

В Восточном Казахстане рак молочной железы на I стадии регистрируют у 58% женщин Устинка

Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival

Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival UT MD Anderson

FDA approves Tukysa combination for HER2-positive breast cancer

The FDA has approved tucatinib plus trastuzumab and pertuzumab as front-line maintenance therapy for adults with unresectable, locally advanced or metastatic HER2-positive breast cancer following induction treatment. Tucatinib (Tukysa, Seagen), an oral tyrosine kinase inhibitor, had previously been approved in 2020 as…

Montefiore joins national study testing early-stage breast cancer treatment without surgery

Montefiore joins national study testing early-stage breast cancer treatment without surgery Bronx Times

Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival | Newswise

Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival | Newswise Newswise

Tumor Traits May Predict Who Responds to Lighter HER2+ Breast Cancer Chemo

Tumor Traits May Predict Who Responds to Lighter HER2+ Breast Cancer Chemo Cure Today

FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Metastatic Breast Cancer

FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Metastatic Breast Cancer Pharmaceutical Executive

FDA Approves Tukysa Combination as Maintenance for HER2-Positive Breast Cancer

FDA Approves Tukysa Combination as Maintenance for HER2-Positive Breast Cancer Cure Today

FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer